2026-05-25 · Weekly · W22 of 2026

Evidence-readiness moves from signal to work surface.

Nine source-backed signals show one operating pressure: regulated teams need evidence that is structured, traceable, reviewable, and reusable. This week connects structured protocols, real-time clinical trials, AI Act classification, real-world evidence, QMSR readiness, device data, ML-enabled device lifecycle control, and market movement. The issue also prepares the first iFeed Regulations artifact planned for Wednesday.

Perspective

Analyst Note

Source Base

Primary-led

Work Route

Signal → Evidence

The Analyst Frame

What changed

More signals now point to structured expectations: protocol templates, live evidence loops, classification records, RWE dialogue routes, QMSR alignment, technical data formats, and lifecycle controls.

What it means

Evidence is becoming an operating surface: something teams need to assign, update, review, reuse, and defend.

iFeed edge

iFeed reads the source, separates fact from interpretation, and turns the implication into a checklist, evidence table, review note, or service path.

Nine Decision Signals

Now

Structured protocol becomes an operating object.

FDA published final M11 Clinical Electronic Structured Harmonised Protocol guidance, with guidance, template, and technical specification files. Protocol content is being formalised as reusable structured evidence, not only a narrative document.

Decision relevance

Clinical operations, medical writing, data standards, and quality teams should plan protocol evidence as structured data that can move across systems and reviews.

Official source · 2026-05-22 · FDA / ICH M11 · Source

Read signal brief →

Now

Real-time clinical-trial evidence stays on the regulator agenda.

FDA announced the extension of the comment period for its Real-Time Clinical Trials request for information to 2026-06-29. The agency continues to frame clinical evidence around faster feedback, active monitoring, and operational learning loops.

Decision relevance

Sponsors and CROs should map what trial data can be captured, reconciled, reviewed, and defended closer to real time.

Official source · 2026-05-27 · FDA RTCT · Source

Read signal brief →

Deadline

EU AI Act classification becomes traceability work.

The European Commission opened a targeted consultation on draft guidelines for classifying high-risk AI systems under the AI Act, with feedback open until 2026-06-23.

Decision relevance

Health-tech and life-sciences teams need a controlled classification file before they build downstream AI governance controls.

Official source · 2026-05-19 · European Commission · Source

Read signal brief →

Watch

Real-world evidence becomes a shared regulator/access language.

MHRA and NICE opened expressions of interest for a Real-World Evidence Scientific Dialogue programme focused on medical devices and health technologies.

Decision relevance

Device and digital-health teams should connect clinical evidence, real-world evidence plans, monitoring, and access questions early.

Official source · 2026-05-20 · MHRA / NICE · Source

Read signal brief →

Horizon

Clinical-trial improvement becomes measurable.

ACT EU reported progress toward 2030 clinical-trial targets, including 19 additional multinational trials above the historical average and 40.5% of trials recruiting within 200 days.

Decision relevance

Sponsors and research organisations should treat trial performance as a managed system with measurable baselines, not a general ambition.

Official source · 2026-05-20 · ACT EU · Source

Read signal brief →

Transition

QMSR readiness becomes evidence architecture.

FDA’s eSTAR page notes that eSTAR version 6.1 has been updated to be consistent with the Quality Management System Regulation (QMSR).

Decision relevance

MedTech teams should connect procedures, records, risks, suppliers, design controls, and submissions before QMSR transition pressure rises.

Official source · 2026-05-01 · FDA eSTAR · Source

Read signal brief →

Data

Clinical device data needs controlled structure.

FDA issued final technical specifications guidance for submitting continuous glucose monitoring data in clinical trials supporting drug and biological product marketing applications.

Decision relevance

Trial data management, biostatistics, clinical operations, and quality teams need to treat device data format and metadata as governance work.

Official source · 2026-05-07 · FDA guidance · Source

Read signal brief →

Watch

ML-enabled device changes require planned evidence.

Health Canada’s pre-market guidance for machine-learning-enabled medical devices sets expectations around transparency, post-market monitoring, and predetermined change control planning.

Decision relevance

AI device teams should prepare lifecycle files that connect model changes, validation evidence, human oversight, risk controls, and post-market monitoring.

Official source · 2026-04-01 · Health Canada · Source

Read signal brief →

Market

Oral GLP-1 shifts the market problem from injection to scale.

EMA’s Committee for Medicinal Products for Human Use recommended adding a daily oral tablet formulation to Wegovy during its 18-21 May 2026 meeting highlights, describing it as the first oral glucagon-like peptide-1 receptor agonist for weight management.

Decision relevance

Commercial, manufacturing, clinical, and pharmacovigilance teams should re-baseline assumptions around patient uptake, supply design, and real-world adherence evidence.

Official source · 2026-05-22 · EMA CHMP · Source

Read signal brief →

Expanded Signal Briefs

Signal 01 of 09 · FDA / ICH · Structured Protocols

The protocol becomes a structured work object.

ICH M11 and FDA’s final guidance point to a practical shift: protocol design, template fields, technical specification, review logic, and downstream trial systems need to speak to one another. The protocol is no longer just a PDF artefact; it is a source object for evidence flow.

Source

FDA / ICH

Date

2026-05-22

Source Class

Official guidance

Governance meaningProtocol structure can reduce ambiguity in review, amendments, system build, and traceability.

iFeed useConvert protocol requirements into owner fields, evidence objects, data standards, and review checkpoints.

View source ↗

Source-to-system protocol object

Guidancewhat must be represented

Templatewhere fields become explicit

Tech Spechow systems can exchange

Trial Buildwhere evidence is reused

Protocolsource object

Ownercontrolled edits

Datastandard fields

Reviewtraceable changes

Signal 02 of 09 · FDA · Real-Time Clinical Trials

Trial evidence moves from packet to stream.

FDA’s Real-Time Clinical Trials work keeps a clear pressure in view: evidence review is moving closer to the running trial. That does not remove quality control; it makes data quality, monitoring logic, and decision records more active.

Source

FDA

Date

2026-05-27

Source Class

Official announcement

Operational meaningEndpoint, safety, and data-quality signals need review paths while the trial is moving.

iFeed useMap live-review workflows into evidence fields: signal, owner, review frequency, action route, and audit trail.

View source ↗

Signal 03 of 09 · European Commission · AI Act Classification

Classification becomes a controlled decision record.

The practical question is not simply whether an AI system is high risk. Teams need traceable logic for intended purpose, actor role, use context, exclusions, and obligation pathway. That record becomes the foundation for later evidence and governance decisions.

Source

European Commission

Date

2026-05-19

Source Class

Official consultation

Governance meaningClassification should be documented as a reviewed decision, not handled as a loose label.

iFeed useBuild a source-linked starter map for AI literacy, classification logic, and governance readiness.

View source ↗

Signal 04 of 09 · MHRA / NICE · Real-World Evidence

RWE becomes a market-access bridge.

The MHRA-NICE dialogue matters because real-world evidence is not only a regulatory evidence issue. For devices and health technologies, it can connect safety, effectiveness, adoption, reimbursement, and stakeholder confidence.

Source

MHRA / NICE

Date

2026-05-20

Source Class

Official programme

Market meaningEvidence readiness increasingly shapes whether a technology can be trusted, adopted, reimbursed, and monitored.

iFeed useTurn RWE questions into a readiness map: data source, population, endpoint, bias control, and decision use.

View source ↗

Signal 05 of 09 · ACT EU · Trial Metrics

Trial competitiveness gets a measurement layer.

When trial targets are tracked publicly, operational performance becomes part of the ecosystem story. Start-up speed, multinational execution, transparency, and inclusion become measurable operating questions.

Source

ACT EU

Date

2026-05-20

Source Class

Official metrics

Operational meaningClinical trial execution can be benchmarked against time, geography, recruitment, and delivery indicators.

iFeed useUse metrics as a decision surface for site strategy, operational design, and evidence planning.

View source ↗

Signal 06 of 09 · FDA eSTAR · QMSR Readiness

QMSR readiness is a traceability exercise.

The Quality Management System Regulation is not only a wording change. For teams preparing device submissions, the question becomes whether procedures, design controls, risk files, supplier records, and submission fields connect cleanly.

Source

FDA eSTAR

Date

2026-05-01

Source Class

Official programme page

Quality meaningQMSR readiness can be checked through evidence links between system controls and submission artefacts.

iFeed useBuild gap tables that link requirement, owner, record, evidence status, and review route.

View source ↗

Signal 07 of 09 · FDA · Device Data

Device signals become submission data.

Continuous glucose monitoring data can support drug and biologic applications only when the signal, metadata, structure, and submission format are controlled. Technical format becomes part of evidence quality.

Source

FDA

Date

2026-05-07

Source Class

Official guidance

Technical meaningDevice-generated data needs traceability from collection through analysis and submission.

iFeed useConvert device-data guidance into a checklist for format, metadata, ownership, validation, and review.

View source ↗

Signal 08 of 09 · Health Canada · ML-Enabled Devices

Model change needs a lifecycle file.

Machine-learning-enabled medical devices are not finished at initial clearance or authorisation. Evidence has to follow intended changes, validation strategy, human oversight, transparency, and post-market monitoring.

Source

Health Canada

Date

2026-04-01

Source Class

Official guidance / watch item

AI governance meaningPredetermined change control planning turns model updates into a governed lifecycle process.

iFeed useMap AI device lifecycle controls into evidence fields that can be reviewed before product or market decisions.

View source ↗

Signal 09 of 09 · EMA CHMP · Oral GLP-1

The market shifts from injection to scale.

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended an oral glucagon-like peptide-1 (GLP-1) receptor agonist formulation for weight management. The operating question shifts toward scale, adherence, access, and pharmacovigilance.

Source

EMA CHMP

Date

2026-05-22

Source Class

Official highlights

Market meaningPatient convenience changes the competitive baseline for weight-management therapies.

Operational useManufacturing, supply, adherence, and real-world evidence assumptions need a fresh model.

View source ↗

The readout: evidence-readiness is becoming operating infrastructure.

The W22 signal is convergence. Protocols need structure. Real-time trials need live review loops. AI classification needs a controlled record. Real-world evidence needs a regulator/access language. QMSR needs evidence architecture. Device data needs technical traceability. ML-enabled devices need lifecycle control.

For regulated teams, the practical capability is not simply reading guidance. It is turning sources into owners, records, review paths, and reusable evidence surfaces.

How this ladders into iFeed work.

This issue leads directly into the iFeed Regulations workstream, starting with the EU AI Act Article 4 AI Literacy Starter Assessment planned for Wednesday.

ChecklistEU AI Act Article 4 AI literacy starter assessment

Evidence tableSource-linked readiness fields and owner prompts

OutreachQA, RA, clinical ops, digital-health and AI governance teams

ServiceCompleted checklist review, evidence-gap report, or readiness sprint

Source Ledger

Structured protocols

FDA / ICH

2026-05-22

Official guidance

Real-time evidence

FDA

2026-05-27